Ensign Peak Advisors, Inc Zentalis Pharmaceuticals, Inc. Transaction History

Ensign Peak Advisors, Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	BUY	$18.07 - $25.6 $778,455 - $1.1 Million	43,080 Added 28.37%	194,933 $3.93 Million
Q3 2022 Nov 14, 2022	BUY	$20.23 - $31.73 $1.38 Million - $2.17 Million	68,327 Added 81.8%	151,853 $3.29 Million
Q4 2021 Feb 11, 2022	BUY	$66.92 - $84.79 $3.28 Million - $4.15 Million	48,946 Added 141.54%	83,526 $7.02 Million
Q3 2021 Nov 12, 2021	SELL	$46.83 - $73.5 $1.4 Million - $2.21 Million	-30,000 Reduced 46.45%	34,580 $2.3 Million
Q2 2021 Aug 13, 2021	BUY	$37.41 - $62.25 $2.11 Million - $3.5 Million	56,280 Added 678.07%	64,580 $3.44 Million
Q4 2020 Feb 12, 2021	BUY	$31.71 - $57.97 $263,193 - $481,151	8,300 New	8,300 $431,000

142

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $171M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.